Reason for request
Indication extension
Summary of opinion
Favourable opinion for reimbursement in the following indication: “KEYTRUDA, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), in the treatment of FIGO 2014 Stage III (extension onto the pelvic wall or lower one-third of the vagina and/or causing hydronephrosis or non-functioning kidney) to IVA (involvement of the mucosa of bladder/rectum -adjacent pelvic organ spread-) with or without involvement of the pelvic and/or para-aortic lymph nodes) locally advanced cervical cancer in adults who have not received prior definitive therapy.”
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of KEYTRUDA (pembrolizumab), in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), is substantial in the indication: “in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), in the treatment of FIGO 2014 Stage III (extension onto the pelvic wall or lower one-third of the vagina and/or causing hydronephrosis or non-functioning kidney) to IVA (involvement of the mucosa of bladder/rectum -adjacent pelvic organ spread-) with or without involvement of the pelvic and/or para-aortic lymph nodes) locally advanced cervical cancer in adults who have not received prior definitive therapy.”
|
Clinical Added Value
| moderate |
Considering:
- demonstration in a randomised, double-blind, phase 3 study (KN-A18 trial, including 56.7% FIGO 2014 stage III - IVA patients) of the superiority of pembrolizumab compared to chemoradiotherapy, for the treatment of FIGO stage IB2-IIB and III - IVA locally advanced cervical cancer in adults who have not received prior definitive therapy, in terms of:
- progression-free survival with an HR = 0.70 (95% CI = [0.55; 0.89]; p = 0.002 < the predefined threshold of 0.0172), 7% patients progressed or died in the experimental group versus 29.0% patients in the control group. The median PFS was not reached in either of the two groups.
- overall survival with an HR = 0.67 (95% CI = [0.50; 0.90]; p = 0.0040 < 0.01026), 2% deaths in the experimental group versus 20.5% patients in the control group. The median OS was not reached in either of the two groups.
And despite:
- the absence of any formal conclusion that can be drawn based on the quality of life findings;
- a safety profile deemed to be acceptable compared to chemoradiotherapy but marked by an excess toxicity with grade ≥ 3 AEs reported in 78.3% of patients in the pembrolizumab group and 70.0% of patients in the placebo group). In addition, 20.6% of patients in the pembrolizumab group and 14.9% of patients in the placebo group had an AE resulting in definitive discontinuation of pembrolizumab treatment.
The Committee deems that KEYTRUDA (pembrolizumab) 25 mg/ml, concentrate for solution for infusion, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), provides a moderate clinical added value (CAV III) compared to chemoradiotherapy.
|
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
ctYPHQE24zyBR7KL